Fact 26 of 26 in the story · Friday 20 November, 22h45
Wegovy : une autorisation envisagée chez les enfants de 6 à 12 ans
L'extension possible de l'autorisation médicale du Wegovy, à base de sémaglutide, aux enfants de 6 à 12 ans est évoquée. Ce développement s'inscrit dans le dossier français des médicaments anti-obésité et de leurs usages encadrés.
In brief
Health event (severity: notable) nationwide, first detected on 20 November 2026 at 22:45. Reported by 1 source (1 article), last updated on 20 November 2026 at 22:45. Part of the story “Anti-obesity drugs in France: controls, reimbursement and off-label uses”.
- Category
- Health
- Severity
- Notable
- Place
National
- Detected
- 20 Nov, 22h45
- Updated
- 20 Nov, 22h45
- Reference
- no.27379
What changed in the story at that point
Un médicament anti-obésité réduit les douleurs d'arthrose du genou
1 article · 1 source · no rated outlet covers this topic yet (public service, agencies, official accounts…)
Story angles
This event does not yet have its own comparison: here is the story's Anti-obesity drugs in France: controls, reimbursement and off-label uses.
The three sides cover the same issue (the arrival of oral Wegovy, French enthusiasm, risks and trafficking), but differ in angle: the left prioritizes testimonies and individual health risks, the center extensively covers the Ifop poll and practical alerts, the right highlights the market explosion, side effects and economic and regulatory aspects.
Left
Highlights personal testimonies (a patient who lost weight without medication, a formerly obese person warning about Wegovy), health risks linked to off-label use and recourse to parallel markets, as well as changes in eating habits.
Centre
Extensively covers the Ifop poll (one in five French people tempted, even without being obese), health professionals' alerts on injections and harmful substances, influencers diverting medications, and customs controls against trafficking.
Right
Highlights the explosion of the appetite suppressant market and the multiplication of side effects, the non-reimbursable nature of oral Wegovy, consultation waiting times and the economic aspects of treatment.
Common points
- =Wegovy is now available in tablet form in France since early November
- =Around one in five French people consider using GLP-1s to lose weight according to the Ifop survey
- =Health professionals and authorities warn about risks and side effects
- =Off-label uses and illegal purchases or parallel markets are reported
Divergences
- ≠The left insists on weight-loss testimonies without medication and individual warnings, an angle little present in the center and on the right
- ≠The right highlights the market explosion, side effects and economic impact, more than the left
- ≠The center develops influencer cases and customs trafficking as a main angle, less central on the left and right
Written by an AI from headlines and extracts only of all events in the story · 14 Nov, 15h44
Lire les sources · 1 article, 1 source
- 22h45e-sante.frWirevia GDELT – Presse française20 NovSémaglutide pour les 6 - 12 ans : vers une autorisation médicale du Wegovy ?
Further reading
Keywords
#Wegovy · #sémaglutide · #enfants · #autorisation
Go up the thread
In the same story
- Wegovy et Mounjaro remboursés : les centres spécialisés de l'obésité saturés20 Nov
- Un médicament anti-obésité réduit les douleurs d'arthrose du genou20 Nov
- Ozempic : un nutritionniste met en garde contre les usages abusifs18 Nov
- Des patients témoignent de leur traitement anti-obésité18 Nov
- Hors critères de la Sécu, le Wegovy coûte plus de 2 300 € par an14 Nov
- Les médicaments anti-obésité explorent de nouveaux usages thérapeutiques14 Nov